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Abstract
Background: Circulating progenitor cells (PCs) are considered to contribute to the remodeling
of atherosclerotic plaques. Their surface receptor CXCR4 plays an important role in the
recruitment of PCs to their target. This study compares the mobilization of PCs and their functional
characteristics in asymptomatic subjects with stable and with unstable carotid plaques. This could
provide insight into plaque remodeling and help to develop biomarkers for plaque stability.
Methods: In 31 subjects with asymptomatic carotid artery stenosis we analyzed the number of
CD133+ PCs, VEGFR2+CD34+ PCs and the surface expression of CXCR4 on CD133+ PCs by flow
cytometry. Subjects underwent bilateral carotid MRI in a 1.5-T scanner in order to allow the
categorization of plaques, following the modified criteria of the American Heart Association.
Results: The number of CD133+ PCs and VEGFR2+CD34+ PCs showed no significant difference
between subjects with stable and unstable carotid plaques. The expression of CXCR4 on CD133+
PCs was higher in subjects with unstable plaques than in subjects with stable plaques (p = 0.009).
Conclusions:  This study demonstrates an association between functional characteristics of
circulating CD133+ PCs and plaque stability in subjects with asymptomatic carotid artery stenosis.
The higher expression of CXCR4 on CD133+ PCs suggests a difference in the recruitment of PCs
to the injured tissue in subjects with unstable plaques and subjects with stable plaques. As surface
expression of CXCR4 on CD133+ PCs differs in subjects with unstable and with stable plaques,
CXCR4 is a promising candidate for a serological biomarker for plaque stability.
Background
Atherosclerotic carotid artery stenosis represents a leading
risk factor for ischemic stroke. The degree of vessel steno-
sis still represents the main parameter for determining
atherosclerotic disease severity. However, the individual
stroke risk of patients presenting with asymptomatic
severe carotid artery stenosis is relatively low considering
that around 11% of these patients experience an ischemic
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stroke over 5 years [1]. These data suggest that a risk strat-
ification based solely on luminal patency fails to reflect
our current understanding of the pathophysiology of
atherosclerosis. Histological studies suggest that plaque
composition is more important than plaque burden:
carotid lesions with intraplaque hemorrhage or a lipid-
rich necrotic core are regarded as unstable, high-risk
plaques [2-4]. In contrast, plaque lesions consisting
mainly of fibrous tissue or containing large amounts of
calcification are regarded as stable plaques [5,6]. High-res-
olution magnetic resonance imaging (MRI) represents a
new technique with the ability to visualize such plaques
non-invasively [7-9]. Based on histological American
Heart Association (AHA) criteria, modified specifically for
MRI use, a classification was introduced by Cai and co-
workers that allows categorization of carotid plaque fea-
tures noninvasively into distinct lesion types (I-VIII)
[4,10,11]. According to this modified classification,
plaque lesions characterized by a lipid-rich necrotic core,
by the presence of a fibrous cap or by intraplaque hemor-
rhage represent lesion types IV-VI and are regarded as
high-risk, unstable plaques that are likely to rupture and
lead to cerebral ischemia [2,3,5,6,12-16]. Previous litera-
ture suggests that inflammation may represent an impor-
tant factor in the progression of atherosclerotic lesions
[17,18]. Yet the precise underlying mechanisms of athero-
sclerosis and plaque formation are still not fully under-
stood.
Circulating progenitor cells (PCs), which are derived from
adult stem cells, are known to contribute to vascular repair
and may play a pivotal role in the development of athero-
sclerotic plaques. Two functions of PCs are of interest in
this context. They are involved in reendothelialization
after endothelial damage, which could be beneficial by
decreasing the development of atherosclerotic lesions
[19]. By contrast, their contribution to neovascularization
could promote the progression of atherosclerosis by
enhancing the entry of inflammatory cells and cytokines
into the arterial wall [20-23].
The number of circulating PCs is reduced in patients with
cardiovascular risk factors by decreased mobilization
from the bone marrow and increased recruitment of PCs
to sites of vascular injury [24,25]. By contrast, mobiliza-
tion of PCs is increased during an ischemic event like
myocardial ischemia and limb ischemia [23,26]. Statins,
which are considered as plaque-stabilizing, increase the
number of PCs in patients with coronary artery disease
[27].
Not only the mobilization of PCs into the blood circula-
tion but also the recruitment to their target, the "homing",
must be considered when observing the function of pro-
genitor cells. CXCR4, a chemokine receptor, that is
expressed on PCs has been reported to play an important
role for the homing of PCs [28]. It interacts with stromal
cell-derived factor 1 (SDF-1), which is expressed by
endothelial cells and fibroblasts and is increased during
tissue damage such as in myocardial ischemia [29,30]. By
analyzing the expression of CXCR4 on PCs it is possible to
study a functional parameter of PCs.
While circulating PCs seem to be reduced in the blood of
patients with carotid plaques, they might still play a role
for the plaque remodeling [31].
The identification of distinct plaque components is
important in correlating PCs with plaque stability. As
plaque imaging by MRI is a reliable and noninvasive
method for distinguishing stable and unstable plaques, it
can be used to determine the stability of a plaque without
the need to obtain a histological sample [9,32,33].
The aim of our study was to analyze the relationship of cir-
culating PCs and their CXCR4 expression with plaque sta-
bility in order to provide insight into the plaque
remodeling and thus find a potential marker for the risk
stratification of plaques.
Methods
Subject Selection
We recruited 31 consecutive patients at our neurovascular
clinic with carotid artery stenosis. Subjects were included
who presented a carotid stenosis >50% diagnosed by
duplex sonography (ECST criteria). Subjects having a his-
tory of TIA or stroke within the previous 6 months were
excluded. Further exclusion criteria were anamnestic
chronic inflammatory, malign, and chronic infectious dis-
eases as well as cardial and peripheral limb ischemia
within the previous 6 months. All subjects gave written
informed consent before inclusion in the study. The
examinations were performed between April and June
2007.
Risk factor evaluation
Medical history, current medication and smoking habits
were assessed. The clinical examination included a physi-
cal status, blood pressure measurement, blood tests, a 12-
lead ECG and an ultrasound examination of the carotid
arteries. Diabetes mellitus was defined as a fasting glucose
level >126 mg/dl, glucose level at any time >200 mg/dl,
use of hypoglycemic agents, or a history of physician-diag-
nosed diabetes mellitus. Hypertension was defined as
systolic blood pressure >140 mmHg or diastolic blood
pressure >90 mmHg in the supine position, or use of anti-
hypertensive medication. Hyperlipidemia was defined as
a fasting cholesterol value >240 mg/dl, low-density lipo-Journal of Angiogenesis Research 2009, 1:10 http://www.jangiogenesis.com/content/1/1/10
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protein (LDL) cholesterol >190 mg/dl, LDL/high-density
lipoprotein (HDL) ratio >4.0, or a history of physician-
diagnosed increased cholesterol.
MRI Protocol
All subjects were imaged with a 1.5-T scanner (Magnetom
Symphony Quantum Gradient; Siemens Medical System;
Germany) with bilateral phased-array surface coils
(PACC-SS15; Machnet B.V., Netherlands). According to
our previously published protocol, four contrast-weighted
images were obtained as follows: 3-dimensional time-of-
flight MR angiography (3D TOF), T1-weighted (T1w), T2-
weighted (T2w), and proton-density-weighted (PDW)
studies of both carotid arteries. The MRI scan was centered
on the carotid bifurcation on the side of the stenosis to
assure proper matching between the contrast-weighted
imaging series of each patient. The imaging sequences
were as follows: 3D TOF: field of view (FOV) 200 mm/
75.0%; repetition time (TR) 43 ms; time to echo (TE) 7.15
ms, number of excitations (NEX) 2. T1w: FOV 160 mm/
100%; TR 700 ms; TE 14 ms; NEX 2. T2w: FOV 160 mm/
100%; TR 700 ms; TE 100 ms; NEX 2. PDW: FOV 160
mm/100%; TR 700 ms; TE 10 ms; NEX 2. Slice thickness
was 1 mm for the 3D TOF and 2 mm for the T1w, T2w,
and PDW images. The longitudinal coverage of each
carotid artery was 72 mm (72 slices) for the 3D TOF and
24 mm (12 slices) for T1w, T2w, and PDW images.
The subjects were positioned on a vacuum pillow to avoid
head-neck region movement during the MRI scan to
ensure proper alignment between the images acquired in
the four contrast-weighted imaging sequences of each
patient.
MR Image Review
Before evaluating the MRI scans, an image quality rating
(4-point scale; 1 = best, 4 = worst) was assigned to all MR
images for each contrast-weighted-image. Image quality =
4 in one of the contrast weightings led to exclusion of the
evaluation procedure. For each patient, a data set of 108
contrast-weighted MR images (72 slices for the 3D TOF
and 12 slices for T1w, T2w, and PDW) of the carotid arter-
ies was obtained. The images were evaluated by two expe-
rienced reviewers. A consensus opinion was reached for
each image analysis. The reviewers were blinded to the
patient's clinical history at the time of image analysis. To
determine the lesion type in accordance with the modi-
fied AHA criteria, the carotid atherosclerotic plaque in the
108 images of each patient was identified and 6 sequen-
tially acquired slices of each contrast weighting in the
region of the minimum lumen area were selected for eval-
uation. The carotid atherosclerotic plaque in these
selected slides was ascribed to one of the six classification
types according to the following modified AHA criteria:
Type I-II shows near-normal wall thickness without calci-
fication. Type III represents diffuse intimal thickening or
small eccentric plaque without calcification. Type IV-V is
characterized by a lipid or necrotic core surrounded by
fibrous tissue with possible calcification. Type VI shows a
complex plaque with possible surface defect, hemorrhage
or thrombus. Type VII represents a calcified lesion. Type
VIII is characterized by a fibrotic plaque without a lipid
core and with possible small calcifications.
Flow Cytometry
For analysis of circulating PCs, blood samples were taken
at the date of the MRI examination and were processed
immediately (<2 h). Mononuclear cells enriched from cit-
rate phosphate dextrose acid-anticoagulated blood sam-
ples by Ficoll (Ficoll-Paque PLUS, Amersham Biosciences,
Uppsala, Sweden) density gradient centrifugation were
stained as previously described by our study group
[34,35].
Vital CD133+ PCs were determined using anti-CD133,
anti-CD34, 7-AAD, and anti-CD45. CD133 and CD34 are
surface markers of progenitor cells. The expression of
CD34 and CD133 diminish with maturation and differ-
entiation [36]. CD45 is present on all human leucocytes.
On CD133+ PCs the expression of CD45 is low [37]. 7-
AAD(7-amino-actinomycin D) was used for the exclusion
of nonviable cells [38].
Vital VEGFR2+CD34+ PCs were determined using anti-
VEGFR2, anti-CD34, 7-AAD, and anti-CD45. VEGFR2 is a
receptor of Vascular Endothelial Growth Factor(VEGF)
that is expressed on endothelial cells [39]. As
VEGFR2+CD34+ PCs express endothelial markers and pro-
genitor markers, they are classified as endothelial progen-
itor cells [40].
Surface expression of the SDF-1 receptor CXCR4 on
CD133+  PCs was analyzed using anti-CXCR4, anti-
CD133, anti-CD45, and 7-AAD. In order to preserve
CXCR4, heparin-blood was incubated with the described
antibodies, Ficoll centrifugation was not performed. Fluo-
rescence isotype-matched antibodies were used as con-
trols. Flow cytometric analysis was performed using a
FACS Calibur (BD Biosciences, Mountain View, CA, USA).
Fluorescence intensity of at least 100 000 cells was
recorded and analyzed using CellQuest software (BD Bio-
sciences). Results of flow cytometry and MRI scans were
analyzed by different investigators, each without knowl-
edge of the other results.
Antibodies used were:
- PE-conjugated anti-CD133 (clone AC133) (Miltenyi
Biotec, Auburn, USA)Journal of Angiogenesis Research 2009, 1:10 http://www.jangiogenesis.com/content/1/1/10
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- FITC-conjugated anti-CD34 (clone 8G12), 7-AAD and
APC-conjugated anti-CD45 (clone 2D1) (Becton Dickin-
son, Heidelberg, Germany)
- PE-conjugated anti-VEGFR2 (clone 89106) and FITC-
conjugated anti-CXCR4 (clone 12G5) (R&D Systems,
Minneapolis, USA).
Statistical Analysis
Differences between two groups were analyzed by Mann-
Whitney U-test for interval variables and by chi-squared
test for categorical variables (SPSS 16.0 for windows). A p-
value < 0.05 was regarded as significant.
Results
Clinical and MRI Data
We recruited 31 subjects with asymptomatic carotid artery
stenosis. Twenty-three plaques were classified as stable
according to the modified AHA-classification (types III,
VII, and VIII) and 8 were classified as unstable (types IV-V
and VI). Figure 1 shows a representative case of lesion type
IV-V, Figure 2 shows a representative case of lesion type
VIII. Subjects with stable plaques did not differ signifi-
cantly from the subjects with unstable plaques concerning
age, sex, and cardiovascular risk factors (Table 1).
Circulating CD133+ Progenitor Cells and VEGFR2+CD34+ 
Progenitor Cells
The number of CD133+ PCs did not differ between sub-
jects with unstable plaques and subjects with stable
plaques (mean [median] ± sem 0.14 [0.07] ± 0.04 cells/μl
vs. 0.09 [0.07] ± 0.03 cells/μl, p = 0.982) (Table 2, Figure
3).
The analysis of VEGFR2+CD34+ PCs presents a similar pat-
tern without significant difference between subjects with
stable plaques and subjects with unstable plaques (mean
[median] ± sem 0.15 [0.12] ± 0.04 cells/μl vs. 0.17 [0.14]
± 0.04 cells/μl, p = 0.219) (Table 2, Figure 4).
Surface Expression of CXCR4 on CD133+ Progenitor Cells
The surface expression of CXCR4 on CD133+ PCs was sig-
nificantly higher in subjects with unstable plaques than in
subjects with stable plaques (mean [median] ± sem 86.74
[87.57] ± 5.64 vs. 65.78 [62.6] ± 3.76, p = 0.009) (Table
2, Figure 5).
Discussion
We have demonstrated that the number of CD133+ PCs
and VEGFR2+CD34+ PCs does not differ significantly in
subjects with stable carotid plaques compared with sub-
jects with unstable carotid plaques. Yet surface expression
of CXCR4 on circulating CD133+ PCs was associated with
plaque instability. Only a limited number of studies have
analyzed the correlation between PCs and atherosclerotic
lesions. Vasa et al. demonstrated that atherosclerotic risk
factors inversely correlate with the number of circulating
VEGFR2+CD34+ PCs [25]. Consistently, subjects with the
presence of carotid, aortic, or femoral plaques presented a
decreased number of PCs. The presence of carotid plaques
in particular entailed a reduction of 48% of
VEGFR2+CD34+  PCs compared with subjects without
plaques [31]. It is therefore supposed that the number of
circulating PCs is associated inversely with the degree of
atherosclerotic disease. Although we can presume a
decreased level of PCs in the subjects of our study because
of their risk profile and the presence of plaques, we did
not observe differences in the number of circulating PCs
Table 1: Baseline Characteristics and Lesion Type
Subjects with Stable Plaques Subjects with Unstable Plaques
(n = 23) (n = 8) p
Age, mean (range) 73 (61-84) 70 (59-84) n.s.
Male, N (%) 17 (73.9%) 5 (62.5%) n.s.
Hypertension, N (%) 21 (91.3%) 7 (87.5%) n.s.
Atrial Fibrillation, N (%) 0 0
Hyperlipidemia, N (%) 17 (73.9%) 7 (87.5%) n.s.
Type II diabetes mellitus, N (%) 6 (26.1%) 2 (25%) n.s.
Current or former smoker, N (%) 13 (56.5%) 5 (62.5%) n.s.
Medication
Statin, N (%) 19 (82.6%) 7 (87.5%) n.s.
Thrombocyte aggregation inhibitors, N (%) 23 (100%) 8 (100%) n.s.
Plaque type, N (%)
III 2 (8.7%)
IV/V 7 (87.5%)
VI 1 (12.5%)
VII 13 (56.5%)
VIII 8 (34.8%)
Data are shown as mean[median] ± semJournal of Angiogenesis Research 2009, 1:10 http://www.jangiogenesis.com/content/1/1/10
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depending on plaque morphology. Thus there is no indi-
cation that different types of plaque influence the mobili-
zation of PCs unequally. But it can not be ruled out that a
higher consumption of PCs compensates a higher mobili-
zation. So it also could be possible that the mobilization
of PCs in subjects with unstable plaques and subjects with
stable plaques differ even if the absolute number of circu-
lating PCs is equal.
As the number of circulating PCs is low, not only their
mobilization from the bone marrow but also their hom-
ing to the damaged tissue is of particular importance. The
cytokine SDF-1 (stromal cell-derived factor 1) and its only
known receptor CXCR4, which is expressed on PCs, seem
to play an important part in the homing process [41,42].
Additionally, the CXCR4/SDF-1 interaction influences
proliferation and mobilization of PCs from the bone mar-
row [43,44]. In addition to the number of circulating PCs,
we therefore also analyzed the expression of their surface
receptor CXCR4, in order to evaluate their homing process
to the affected tissue. In contrast to other studies we did
not evaluate the number of CXCR4+ cells but the expres-
sion of CXCR4 on CD133+ PCs as a functional parameter.
Example of lesion type IV-V in the right internal carotid  artery Figure 1
Example of lesion type IV-V in the right internal 
carotid artery. The necrotic core (←) shows low-signal 
intensity (SI) on both T1w and TOF images, but low SI to iso-
SI on PDW and T2w images. Original magnification × 25.
TOF
PD T2
T1 TOF
PD T2
T1
Example of lesion type VIII in the right internal carotid artery Figure 2
Example of lesion type VIII in the right internal 
carotid artery. Lesion type VIII (←) in the right internal 
carotid artery. MR images show iso- to slightly high-SI. Origi-
nal magnification × 25.
Number of CD133+ progenitor cells Figure 3
Number of CD133+ progenitor cells. Boxplot demon-
strating the number of CD133+ progenitor cells (/μl) in sub-
jects with stable plaques and subjects with unstable plaques. 
The top of the box represents the 75th percentile, the bot-
tom of the box represents the 25th percentile, the center 
horizontal line represents the 50th percentile. The whiskers 
represent the highest and lowest values that are not outliers 
or extreme values. Outliers (between 1.5 and 3 times the 
interquartile range) are represented by circles and extreme 
values (more than 3 times the interquartile range) by aster-
isks.
n.s.Journal of Angiogenesis Research 2009, 1:10 http://www.jangiogenesis.com/content/1/1/10
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This is the first study to show an increased expression of
CXCR4 on CD133+ PCs in subjects with unstable plaques
compared with subjects with stable plaques. Our results
suggest that not the number of circulating PCs but their
activation is associated with severity of atherosclerotic dis-
ease. As we are not able to detect the functional PCs in the
injured tissue, analyzing CXCR4 on circulating PCs pro-
vides a promising auxiliary parameter.
Our results indicate that the recruitment of the PCs to the
injured tissue in patients with unstable plaques may be
elevated and the PCs can better become functional even if
patients with unstable plaques present the same number
of PCs as patients with stable plaques. There are two pos-
sible mechanisms of an increased recruitment of PCs to
the plaque in patients with unstable plaques.
First, unstable plaques could activate the endogenous
repair mechanism by recruiting PCs to the plaques. As PCs
are involved in the reendothelialization of damaged
endothelium, PCs are regarded as an endogenous repair
mechanism [19]. Because of the enhanced presence of leu-
kocytes in unstable plaques and their production of
cytokines, CXCR4 can be upregulated and can therefore
contribute to the recruitment of PCs to the plaque via the
CXCR4/SDF-1 interaction. Thus the inflammatory process
of an unstable plaque could trigger enhanced recruitment
of PCs.
Another mechanism could be the potential unfavorable
effect of PCs by induction of neoangiogenesis, thereby
causing plaque instability. The role of PCs in neovascular-
ization has been investigated by several groups [45-48]. In
atherosclerotic lesions, neoangiogenesis could result in
the entry of inflammatory cells and cytokines into the
lesions and therefore promote the instability of plaques.
Table 2: Progenitor Cells in Subjects with Unstable Plaques and Subjects with Stable Plaques
Subjects with Stable Plaques Subjects with Unstable Plaques
(n = 23) (n = 8) p
CD133+ progenitor cells (cells/μl) 0.14 [0.07] ± 0.04 0.09 [0.07] ± 0.03 n.s.
VEGFR2+CD34+ progenitor cells (cells/μl) 0.15 [0.12] ± 0.04 0.17 [0.14] ± 0.04 n.s.
CXCR4 surface expression on CD133+ progenitor cells 65.78 [62.6] ± 3.76 86.74 [87.57] ± 5.64 0.009
Number of VEGFR2+CD34+ progenitor cells Figure 4
Number of VEGFR2+CD34+ progenitor cells. Boxplot 
demonstrating the number of VEGFR2+CD34+ progenitor 
cells (/μl) in subjects with stable plaques and subjects with 
unstable plaques. The top of the box represents the 75th 
percentile, the bottom of the box represents the 25th per-
centile, the center horizontal line represents the 50th per-
centile. The whiskers represent the highest and lowest values 
that are not outliers or extreme values. Outliers (between 
1.5 and 3 times the interquartile range) are represented by 
circles and extreme values (more than 3 times the interquar-
tile range) by asterisks.
n.s.
Surface expression of CXCR4 on CD133+ progenitor cells Figure 5
Surface expression of CXCR4 on CD133+ progenitor 
cells. Boxplot demonstrating the surface expression of 
CXCR4 on CD133+ progenitor cells in subjects with stable 
plaques and subjects with unstable plaques. The top of the 
box represents the 75th percentile, the bottom of the box 
represents the 25th percentile, the center horizontal line 
represents the 50th percentile. The whiskers represent the 
highest and lowest values.
p<0,01Journal of Angiogenesis Research 2009, 1:10 http://www.jangiogenesis.com/content/1/1/10
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Neovessel content was significantly increased in ruptured
plaques compared with nonruptured plaques in the
human aorta, so neovascularization could also contribute
to plaque rupture [49,50]. Therefore, an enhanced recruit-
ment of PCs to the plaques could aggravate plaque insta-
bility. However, the MRI-protocol used for our study did
not allow to assess plaque neovascularisation. So we were
not able to analyze a possible association between plaque
neovascularisation and PCs.
It is also thinkable that the lower expression of CXCR4 in
subjects with stable plaques suggests the occurrence of
premature PCs caused by a higher consumption of PCs.
The lower expression of CXCR4 on CD133+ PCs could
therefore be seen as a marker for a higher consumption of
CD133+ PCs meaning a raised endogenous repair mecha-
nism.
As surface expression of CXCR4 on CD133+ PCs is signifi-
cantly higher in subjects with unstable plaques than in
subjects with stable plaques, CXCR4 represents a promis-
ing candidate for a serological biomarker of plaque stabil-
ity. Because of the low number of analyzed subjects, the
results must be confirmed in a larger study.
Conclusions
Our results demonstrate an association between circulat-
ing PCs and plaque stability in carotid artery stenosis.
Subjects with unstable plaques showed a higher expres-
sion of the surface receptor CXCR4 on CD133+ PCs than
did subjects with stable plaques, suggesting differences in
the recruitment of PCs to their target, even if the number
of circulating PCs was equal. PCs may therefore play a role
in the endogenous repair mechanism in atherosclerotic
lesions. On the other hand, it must be kept in mind that
PCs may also have a negative effect on plaque stability by
stimulation of neovascularization.
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